Our Company

At Steriscience, we bring together scientific precision, high quality manufacturing, strong market knowledge to provide patients with best-in-class care.

Steriscience focuses on creating value-added sterile injectables that bridge the gap at hospitals by streamlining workflows, reducing wastage of key resources, and increasing efficiency that solves for challenges of healthcare professionals across the globe.

The global supply of sterile injectables is limited by consistent supply chain challenges, lack of sterility assurance and technical complexities in R&D. With a product portfolio designed to increase patient access and four state-of-the-art facilities focused on ensuring supply security, Steriscience is poised to become a leading player in the global injectables domain.


To become a global partner of choice for sterile injectables.


To be a global injectables player providing patients access to critical hospital medications and improving patient care

Our Values

Our objective is to achieve our desired goals by embracing a set of values that form the core of all our behaviour, actions, decisions, and processes. We live our values by demonstrating the highest levels of ethics to deliver our mission. The three core values for Steriscience are:

Operate with the highest degree of integrity and transparency with no compromises at all. By integrity, we mean our people, products, and processes display integrity always.


Collaborate with team members and colleagues to deliver synergy and excellence in all the activities, actions, and decisions such that we deliver high customer advocacy.

  • Be non-hierarchical and inclusive
  • Transparent and comprehensive communication with customers
  • Strive to ensure that our products are delivered in time giving comfort to the customers and partners

Display entrepreneurial zeal towards work and deliver safe and superior products efficiently.

• Achieve cost leadership via operational excellence
• Innovate to delight our employees, customers, and community
• Commit to the highest standards of quality

Ensure safety and well-being of our employees and achieve ESG (Environment, Social, Governance) criteria.

Our Legacy

Steriscience’ s roots can be found in Agila Specialties (part of Strides Group up to 2012-13) which was a leading global player in the sterile injectables space, after which it was acquired through strategic transaction by Mylan Inc. (now Viatris Inc.).

With a portfolio of 200+ ANDA filings in the US, 180+ filings in other developed markets and nine manufacturing facilities globally, accredited by global regulatory authorities including USFDA, MHRA & EMA, Agila had become synonymous with the highest standards of quality and trust in the pharmaceutical industry. The culture of ‘one quality’ ensured Agila carried a strong track record of over 65 successful inspections over 15 years. In 2012, Agila played a pivotal role in addressing the drug shortage crisis in US with over 250 drugs, including key oncology drugs and anti-infectives, declared in short supply – ensuring that patients had access to these critical and life-saving drugs. The transaction with Mylan valued Agila at close to a 1.6 billion dollars, making it one of the most significant transactions in the Indian Pharma space.

Post the completion of the non-compete agreement with Mylan; the year 2020 saw the inception of Steriscience to continue and build on the legacy of Agila with a redefined strategy meeting the unmet demand of the specialty and sterile injectable space.

Within a short time, Steriscience has grown rapidly to achieve significant scale, with over 30 product developments completed, 4 state-of-the-art manufacturing facilities acquired, and products launched in global markets including the US.


  • 2020

    Inception & acquisition of EU GMP approved facility in Poland

  • 2021

    2 US FDA facilities acquired in India & majority stake acquired in Brooks’ Carbapenems facility, India.

  • 2022

    First EU product approval & first ANDA approval and product launch in US

  • 2023

    Received US FDA approvals for the Brooks’ Carbapenems & Poland General Injectable facilities